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Summary
Objective: To assess the relationship of biochemical markers and radiographic signs of osteoarthritis (ROA) in the subjects with symptomatic
osteoarthritis (OA) at multiple sites of the Genetics osteoARthritis and Progression (GARP) study.
Methods: We have measured eight biochemical markers, representing tissue turnover of cartilage, bone, synovium, and inﬂammation. ROA
was assessed in the knees, hips, hands, vertebral facet joints and spinal disc degeneration (DD) by using the Kellgren score. A proportionate
score was subsequently made for each joint location based on the number of joints with ROA. Principal component and linear mixed model
analyses were applied to analyze the data.
Results: Three different clusters of markers were identiﬁed that may reﬂect different pathophysiological processes of OA. The ﬁrst component
appeared to be reﬂected by structural markers of cartilage and bone turnover and associated especially in subjects with hip ROA. The second
component was reﬂected by a marker of inﬂammation and was associated with knee ROA, high Western Ontario and McMaster Universities
(WOMAC) scores and body mass index (BMI). The third component included markers of cartilage turnover and was associated with ROA at
hands, spine as well as age. High familial aggregation was observed for serum cartilage oligomeric matrix protein (S-COMP) (70%) and serum
N-propeptide of collagen type IIA (S-PIIANP) (62%).
Conclusion: Using a large well-characterized study and eight biochemical markers, we were able to observe three components that may re-
ﬂect different molecular mechanisms (bone, cartilage, synovium turnover and inﬂammation). Our data suggested that these components con-
tribute differently to ROA at different joint sites.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: ACR American College of Rheumatology, BMI body mass index, CIL conﬁdence interval limits, CMC1 ﬁrst carpometacarpal,
COMP serum cartilage oligomeric matrix protein, CTX-I C-terminal cross linking telopeptide of type I collagen, CTX-II C-terminal cross linking
telopeptide of type II collagen, DD disc degeneration, DIP distal interphalangeal, GARP Genetics osteoARthritis and Progression, GlceGal-
PYD urinary glucosylegalactosyl PYriDinoline, HRT hormone replacement therapy, HsCRP serum high sensitive C-reactive protein, MCP
metacarpophalangeal, OA osteoarthritis, OC osteocalcin, PA posterioreanterior, PIIANP serum N-propeptide of collagen type IIA, PIP prox-
imal interphalangeal, ROA radiographic signs of osteoarthritis, S serum, TIINE collagen type II neoepitope, U urinary, WOMAC Western
Ontario and McMaster Universities.
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SocietyIntroduction
Osteoarthritis (OA) is a joint disease characterized by de-
generation of articular cartilage and bone remodeling that
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Received 13 April 2006; revision accepted 9 September 2006.3clinically results in pain and joint stiffness. OA is recognized
as a complex disease for which different deﬁnitions exist.
Such deﬁnitions may be considered as distinct entities of
the disease, potentially caused by different underlying path-
ophysiological processes1.
Structural damage of the cartilage is usually assessed by
radiographic characteristics which, however, lack sensitivity
for monitoring the disease activity and progression of the
OA2. Biochemical markers have been identiﬁed that reﬂect
bone, cartilage and synovium turnover which may have the79
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tissue remodeling and inﬂammatory responses. Such
markers may be useful in identifying more speciﬁcally and
sensitively, those subjects at risk for incidence of OA and
its progression. Furthermore, since some of these markers
reﬂect different aspects of the OA process by measuring
separately cartilage, bone and synovial tissue turnover,
they may discriminate patients not only on the basis of
the established OA deﬁnitions but also on the underlying
pathophysiology of the different OA subtypes. Other
markers may be correlated to such an extent that they
may provide redundant data. Among the markers mea-
sured, we3 and others4e7 have previously reported that uri-
nary C-terminal cross linking telopeptide of type II collagen
(U-CTX-II) levels are associated to cartilage damage. To
date, U-CTX-II appears as one of the most interesting
biological of joint damage as assessed on X-rays in OA,
U-CTX-II, however, lacked speciﬁcity to reﬂect OA at
speciﬁc joint locations and different pathophysiological pro-
cesses involved in OA3,8. In the present study, we investi-
gated the relationship between the levels of eight
biochemical markers and OA in different joints in sibling
pairs of the Genetics osteoARthritis and Progression
(GARP) study. The classiﬁcation of OA patients by multiple
biochemical markers that reﬂect different but also correlated
pathophysiologic processes, may gain power by categoriz-
ing the biochemical markers into distinct components,
based on their pattern of occurrence within subjects. In
order to determine which clusters of biochemical markers
occur within subjects with OA at multiple joint sites, we per-
formed factor analysis. Using this information we performed
mixed model regression analysis to determine whether
these factors coincide with total and joint site speciﬁc radio-
graphic signs of OA (ROA) scores. Since we studied sibling
pairs, we had the opportunity to estimate the heritability of
the marker levels.
Patients and methods
THE GARP STUDY
The primary objective of the ongoing GARP study, which
consists of Caucasian sib pairs of Dutch ancestry affected
predominantly with symptomatic OA at multiple sites, is to
identify genetic determinants of OA susceptibility and pro-
gression. Details of the ascertainment have been described
elsewhere9. Symptomatic OA of a joint within the study was
deﬁned as described below. Informed consent was ob-
tained from all patients.
Probands (aged 40e70 years) and their siblings were in-
cluded in the GARP study with OA at multiple joint sites of
the hand, or with symptomatic OA in two or more of the fol-
lowing joint sites: hand, spine (cervical or lumbar), knee or
hip9. Subjects with symptomatic OA in just one joint site
were required to have structural abnormalities in at least
one other joint site, deﬁned by the presence of radiographic
features in either hip, knee, hand or spine or the presence
of two or more Heberden nodes, Bouchard nodes or squar-
ing of at least one carpometacarpal joint on physical exam-
ination. Symptomatic OA in the knee and hip was deﬁned
according to the American College of Rheumatology
(ACR) recommendations for knee and hip OA10,11. Knee
OA was deﬁned as pain or stiffness for most days of the
preceding month and osteophytes at the joint margins of
the tibiofemoral joint (X-ray spurs). Hip OA was deﬁned
as pain or stiffness in the groin and hip region on most
days of the preceding month in addition to femoral oracetabular osteophytes or axial joint space narrowing on
radiography. Spine OA (cervical and lumbar) was deﬁned
as pain or stiffness in the spine on most days of the preceding
month, in addition to a KellgreneLawrence score of 2 in at
least one disc or one apophyseal joint.
OA in hand joints was deﬁned according to the ACR cri-
teria12 as pain or stiffness on most days of the preceding
month in addition to three of the following four criteria:
bony swelling of 2 of the 10 selected joints (bilateral distal
interphalangeal [DIP] joints 2þ 3, bilateral proximal inter-
phalangeal [PIP] joints 2þ 3, and ﬁrst carpometacarpal
[CMC1] joints), bony swelling of 2 DIP joints, <3 swollen
metacarpophalangeal (MCP) joints, and deformity of at
least one of the 10 selected joints.
Conventional radiographs of the hands (dorso-volar),
knees (posterioreanterior [PA] ﬁxed-ﬂexion and lateral),
hips (PA), lumbar (PA and lateral) and cervical spine (ante-
rioreposterior, lateral and transbuccal) were obtained for all
participants. This was performed in a standardized manner,
by a single experienced radiology technician, with a ﬁxed
ﬁlm-focus distance and a ﬁxed joint position. Radiographs
were scored by a single experienced musculoskeletal radi-
ologist for osteophytes in the knees and hips, and joint
space narrowing in the hips. In addition to the hands
(DIPs, PIPs, and CMC1), the discs and apophyseal joints
of the cervical and lumbar spine, the hips and the tibio-
femoral joints of the knee were also scored according to
the KellgreneLawrence scale with the help of the original
atlas13. ROA were deﬁned according to Kellgren scoring
system.
Intrareader variability for the different joint sites, scored
by the KellgreneLawrence method, was assessed: the in-
traclass correlation coefﬁcient (ICC, with 95% conﬁdence
interval) was for the hands, 0.95 (0.92e0.96); for the knees
(tibiofemoral), 0.92 (0.86e0.96); for the hips, 0.95 (0.92e
0.98); for the cervical spine (apophyseal and disc), 0.71
(0.52e0.84); and for the lumbar spine (apophyseal and
disc), 0.67 (0.46e0.81). Intrareader variability was based
on an examination of 40 radiographs that were selected
randomly throughout the duration of the study period and
were blinded for any patient characteristics.
Deﬁnite ROA at a particular joint site was deﬁned as
a Kellgren score of two or higher. The Western Ontario
and McMaster Universities Osteoarthritis index (WOMAC)
was used to assess pain and physical functioning of the
lower extremes. This questionnaire contains questions on
pain, stiffness, and disability in the lower extremities result-
ing from day to day activities. Radiographic and symptom-
atic OA scoring, in addition to intrareader variability
assessed as ICCs, has been described in detail elsewhere9.
In the present paper we deﬁned a proportionate score for
each joint location based on the number of joints with ROA
identical as described previously3. The speciﬁc ROA scores
used may represent a score proportional to cartilage abnor-
malities at each joint location. Cartilage or bone turnover
products are not expected from arthroplastic joints except
for recent joint replacements14. Therefore, subjects with re-
cent joint replacements (<1 year) were considered as ROA
present whereas all other joints with replacements as ROA
absent. In the GARP study seven and one subjects had un-
dergone, respectively, uni- and bilateral knee replacements
and 23 and 15 for, respectively, uni- and bilateral hip re-
placements. Of them ﬁve had a recent hip replacement
and one a recent knee replacement.
TheGARP study consists of 382 subjects (312women and
70 men). Of the women 260 (83%) were postmenopausal,
including eight women who currently used hormone
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have recently been shown to inﬂuence some biochemical
markers15 postmenopausal women not on HRT were se-
lected (N¼ 252). The present study was performed in 222
postmenopausal women not on HRT, and 67 men from
whom we had levels available of all biochemical markers.
BIOCHEMICAL ANALYSIS
For each participant of the GARP study, we have col-
lected at the same time non-fasted second void morning
urine and serum samples. Samples were stored within 4 h
at 80C until measurement was performed. All biochemi-
cal markers were measured by a specialized laboratory
(Synarc Lyon, France), except for urinary glucosylegalacto-
syl pyridinoline (U-GlceGal-PYD) (INSERM research unit
403, Lyon, France) and urinary collagen type II neoepitope
(U-TIINE) (Pﬁzer Global Research & Development, Ann
Arbor, USA).
Markers of bone turnover
Serum total osteocalcin (S-total OC), a speciﬁc marker of
bone formation, was measured by a two-site assay measur-
ing both intact and N-mid-peptide using an automatic sys-
tem (Elecsys, Roche Diagnostic, Manheim, Germany).
Measuring N-mid-peptide the main proteolytic fragment of
OC allows correction for the potential degradation of OC
in vitro and the determination of precise measurements.
Intra- and inter-assay coefﬁcients of variation (CVs) are
lower 2.5% and 3%, respectively.
Urinary excretion of b isomerized C-terminal cross linking
telopeptide of type I collagen (U-CTX-I) was measured by
the Crosslaps enzyme-linked immunosorbent assay
(ELISA) (Nordic Biosciences, Herlev, Denmark)16. This as-
say uses a polyclonal antiserum raised against the b isomer-
ized EKAH b DGGR sequence of the C-telopeptide of a1
chains of human type I collagen. Intra- and inter-assay
CVs are below 3% and 10%, respectively.
Markers of cartilage turnover
Urinary CTX-II was measured using an ELISA based on
a monoclonal antibody raised against the EKGPDP linear
6-amino acid epitope of the CII C-telopeptide (CartiLaps:
Nordic Bioscience, Herlev, Denmark). Intra- and inter-assay
variations were lower than 9% and 11%, respectively.
Serum N-propeptide of collagen type IIA (S-PIIANP) was
measured using a newly developed ELISA using a poly-
clonal antibody raised against recombinant glutathionein-
S-transferase-human type II procollagen exon 2 fusion
protein17. This antibody is speciﬁc for the type IIA of the
N-propeptide of type II collagen and Western-blot analysis
of human OA serum showed that it does not cross-react
with circulating proteins which share homologies with
N-propeptide of collagen type IIA (PIIANP) sequence such
as thrombospondin and von-Willebrand factor18. The ELISA
used in the current study employed the same antibody and
standard than the one used previously19, but in a different
assay format. This technical modiﬁcation which did not alter
the speciﬁcity of the assay resulted in improved precision
and increase in the absolute serum levels of PIIANP. Intra-
and inter-assay CVs were lower than 10%.
Serum cartilage oligomeric matrix protein (S-COMP) was
measured by a two-site immunoassay (COMP ELISA kit,
AnaMar Medical, Lund, Sweden). Intra- and inter-assay
CVs (%) are below 7% and 8%, respectively.Quantitation of urinary collagen type II neoepitope
(U-TIINE)-containing 45-mer peptides with 5-hydroxyproline
(HyP) was performed by 2D LCeMS/MS, utilizing an
HP1100 high performance liquid chromatography (HPLC)
system (Agilent, Palo Alto, CA) composed of a quaternary
pump, a CTC Analytics HTS PAL autosampler (LEAP Tech-
nologies, Carrboro, NC), and switching valve plumbed in-
line with another HP1100 pump and interfaced to an API
4000 triple quadrupole mass spectrometer (MDS-Sciex,
Toronto, Canada) operated in the positive ion electrospray
and multiple-reaction-monitoring (MRM) modes. A 45-mer
peptide containing 5-Hyp that was deuterated (d5) at the
C-terminal glutamine residue was used as an internal stan-
dard. For the immunoafﬁnity/reversed-phase LCeMS/MS
analyses, urine samples diluted in 50 mM ammonium ace-
tate were injected onto an immunoafﬁnity column prepared
by cross linking 5109 antibody, which speciﬁcally recog-
nizes a unique sequence of type II collagen (GEPGDDGPS)
adjacent to the neoepitope on the 3/4-length fragment20, to
protein G-Poros material. The column was then washed
for 3 min with 50 mM NH4OAc, pH 7, at 1 mL/min, following
which the valve was switched and the captured peptides
were eluted off the immunoafﬁnity column with a 1% formic
acid solution onto a C-18 peptide macro trapping column
(Michrom BioResources, Auburn, CA) for another 3 min.
Peptides were then eluted off the trapping column onto
a 2.1 100 mm C-18 analytical column (Keystone Scien-
tiﬁc, Bellefonte, PA) with a 10-min gradient of 95% H2O,
1% HCOOH to 65% CH3CN, 1% HCOOH.
Selected 45-mer peptides in urine (referred to hereafter
U-TIINE) were speciﬁcally detected by monitoring HPLC elu-
tion times and ion pairs corresponding to the parent and spe-
ciﬁc fragment ion mass/charge values of 1038.8/568.3 and
1040.3/573.3 for 45-mer TIINE and for its deuterated internal
standard, respectively. Analyte concentrations were deter-
mined by comparing the LCeMS/MS peak areas to that of
deuterated internal standard. Standard analyte curves were
analyzed prior to, and following, assay of the study samples
to ensure equivalent instrument responses for both the ana-
lyte and internal standard. The LCeMS/MS assay was per-
formed by Quest Pharmaceutical Services, LLC (Newark,
DL). The inter-assay precision, determined as the CV,
ranged from 4.0% to 8.7%, increasing to 12.3% at the
LLOQ. Inter-run accuracy ranged from 0.6% to 2.7% relative
error, with 14.2% at the LLOQ. Concentrations of U-TIINE
(ng/mL) were normalized for the urinary creatinine (Cr) con-
centration (mM/mL), and the units reported for the corrected
U-TIINE concentrations are ng/mM Cr.
Markers of synovium and inflammation
U-GlceGal-PYD a non-reducible cross link of collagen
molecules which is present in human synovial tissue and
is released during its destruction was measured as previ-
ously described21. Intra- and inter-assay CVs are below
8% and 11%, respectively. Serum high sensitive C-reactive
protein (S-HsCRP) was assayed using an ultrasensitive
immunonephelometry method (N Latex CRP mono,
Behringwerke AG, Marburg, Germany) on a BNA Behring
nephelometer. The intra- and inter-assay variations are
lower than 5% and the detection limit is of 0.2 mg/
Lon non-hydrolyzed samples by HPLC.
STATISTICAL ANALYSIS
Familial aggregation (heritability) of the biochemical
marker levels was estimated by comparing twice the
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heritability estimates indicate the fraction of the total vari-
ance that is explained by shared genetic and environmental
factors. Estimates were adjusted for the presence of total
ROA score, body mass index (BMI), age and sex.
Principal component analysis (PCA) was to reduce the
data of the biochemical markers that are correlated. The
eight biochemical markers were entered in the PCA in addi-
tion to age and BMI. We used both empirical criteria (per-
centage of variance explained by factors and scree plots)
and interpretability in determining the number of factors. Us-
ing Eigen values >1, three factors were suggested. We ex-
plored the interpretability of these factors after applying
a Varimax rotation with Kaiser Normalization. For each fac-
tor, a score was computed as the average of joint measures
that loaded signiﬁcantly on that factor with a factor loading
of at least 0.4. A factor loading represents the linear rela-
tionship (Pearson correlation under Varimax rotation) be-
tween a variable and a factor. Factor loadings >0.4 are
frequently considered to be signiﬁcant22. In interpreting
the rotated factor pattern, in our study an item was said to
load on a given factor if the factor loading was 0.4 for
that factor and <0.4 for the others.
In order to assess the relationships between OA charac-
teristics and the clusters of biochemical markers, a mixed
model regression analyses were performed using SPSS
version 11 (SPSS, Chicago, IL, USA). The extracted clus-
ters of the biochemical marker levels were used as depen-
dent variable and as co-variables clinical symptoms and
sex in addition to either the total ROA score (0e10) or the
speciﬁc ROA scores as deﬁned above in knee (0e2), hip
(0e2), hand (0e2), facet joints (0e2), and spinal disc de-
generation (DD) (0e2). In the mixed model analysis, we in-
cluded family identity numbers (representing family
relations) as random variables in order to model the familial
dependencies that might occur for the biochemical marker
levels. Results of the mixed model analyses are expressed
as estimates (b) that represent the association between in-
creasing ROA grades and clinical symptoms with clusters of
biochemical marker levels including BMI and age. The esti-
mates, however, should be interpreted relative to the
ranges of the scores that are equal for knee, facet, hip
and hand and DD (0e2), however, larger for the total
ROA score (0e10) and clinical symptoms (0e100). Be-
cause CTX-I, CTX-II, PIIANP, and high sensitive C-reactive
protein (HsCRP) levels were not normally distributed, data
were logarithmically transformed in these analyses.
Results
Table I shows the characteristics of sample of the GARP
study used in the current analysis. Of the 289 patients 77%
were female with a large prevalence of spinal DD and facet
ROA and consisted of 144 pairs. Although the mean age of
this study group (61.4 years) was slightly higher as com-
pared to the total group (60.3 years) characteristics were
comparable. Table II shows for each marker the mean
with the standard deviation (SD), and the median with the
interquartile range (IQR). As shown by the differences in
mean and median levels, the CTX-I, CTX-II, PIIANP, TIINE
and HsCRP levels were not normally distributed. In the
analyses the logarithm of these levels was used. Observed
levels were similar as detected in previous studies4.
Familial aggregation of the biochemical marker levels was
estimated in the sibling pairs. Especially cartilage oligo-
meric matrix protein (COMP) and PIIANP show high andsigniﬁcant heritability estimates of 0.70, 95% conﬁdence in-
terval limits (CIL) 0.39e1.00 and 0.62, 95% CIL 0.25e0.99,
respectively (Table II).
ASSOCIATION OF BIOCHEMICAL MARKERS
As can be expected from markers that reﬂect turnover of
cartilage, bone, and synovial tissue within subjects with OA
the levels measured were correlated (results not shown).
High correlations (coefﬁcients between 0.4 and 0.7) were
observed for CTX-II with TIINE, CTX-I and glucosyle
galactosyl pyridinoline (GlceGal-PYD) whereas moderate
(coefﬁcients 0.3e0.2) between CTX-II and total OC, CTX-I
and BMI, age and GlceGal-PYD and BMI and HsCRP.
For the remaining markers correlations were low, between
0.1 and 0.2 (results not shown).
To reduce the correlated biochemical marker data to in-
dependent components in which these variables cluster,
PCA including all biochemical marker levels, age, and
BMI was performed. Table III shows the three components
that were extracted. The coefﬁcients depicted in Table III
explain how well each individual marker is represented
within the clusters. The marker levels of CTX-I, CTX-II,
TIINE, total OC and GlceGal-PYD levels loaded together
on the ﬁrst component, explaining 27% of the variance
(Eigen value¼ 2.7). The second component, explaining
18% of the variance (Eigen value¼ 1.8), is represented
by subjects with high BMI, systemic inﬂammation (HsCRP).
The third component, explaining 12% of the variance (Eigen
value¼ 1.2), is represented by subjects with high PIIANP
(collagen synthesis), COMP (cartilage turnover), and age.
Subsequently the relationship between the three compo-
nents and the presence of OA characteristics was investi-
gated by mixed model regression analysis. The ﬁrst part
of Table IV shows that the total ROA score (0e10) contrib-
uted mainly to components 1 and 2 (P-value¼ 0.001 and
Table I
Characteristics and frequencies of ROA of the sample of the GARP
study (N¼ 289)
Characteristics GARP study* ROA scorey
0 1 2
Total number
of subjects
289 (1.0)
Hip (%) 86 (30)z 222 (77) 42 (15) 25 (9)
Knee (%) 121 (42)z 172 (60) 69 (24) 48 (17)
Hand (%) 237 (82)z 120 (42) 89 (31) 80 (28)
Facet (%) 287 (99)z 103 (36) 134 (46) 52 (18)
DD (%) 264 (91)z 84 (29) 139 (48) 66 (23)
WOMAC median (range) 22.1 (95)
Age mean (SD) 61.4 (7.0)
BMI mean (SD) 27.0 (4.5)
Women (%) 222 (77)
*Studied sample consists of postmenopausal women not on
HTR and men for whom ROA scores and biochemical marker
levels were available.
yIndicated are the number of individuals with, respectively, ROA
scores of 0e2 for hip, knee, hand, facet and discus degeneration of
the spine. ROA scores of joint replacements which occurred >1
year ago were scored as ROA absent (see also Materials and
methods).
zNumbers represent patients within GARP with uni- or bilateral
ROA at the speciﬁc joint location including subjects with uni- and/
or bilateral joint replacement (N¼ 31 for hip and N¼ 6 for knee
for this sample).
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Biochemical marker levels of the sample of the GARP study (N¼ 289)
Process Mean (SD) Median (IQR) Heritability*(95% CIL)
Cartilage
U-CTX-II (ng/mmol creat) Degradation 221 (180) 265 (168) 0.35 (0.04e0.74)
U-TIINE (ng/ml) Degradation 135 (104) 115 (82) 0.31 (0.05e0.68)
S-COMP (U/L) Turnover 11.4 (4.1) 11.9 (3.3) 0.70 (0.39e1.00)
S-PIIANP (ng/ml) Synthesis 182 (121) 207 (98) 0.62 (0.25e0.99)
Bone
U-CTX-I (mg/mmol creat) Resorption 161 (116) 177 (101) 0.54 (0.19e0.89)
S-total OC (mg/L) Formation 21.7 (10.1) 22.7 (9.0) 0.34 (0.01e0.67)
Synovial
U-GlceGal-PYD (nmol/mmol creat) Synovial tissue turnover 4.8 (2.4) 5.4 (2.1) 0.51 (0.15e0.87)
Inﬂammation
S-HsCRP (mg/L) Systemic 1.8 (2.8) 3.3 (5.0) 0.22 (0.14e0.58)
*Familial aggregation of levels was estimated by comparing the within and between covariance of the sibling pairs. Estimates were adjusted
for presence of total ROA score, BMI, age and sex.0.001, respectively). These two components may be inﬂu-
enced by ROA at a combination of multiple joint sites. In or-
der to investigate whether ROA at speciﬁc joint sites cluster
to these components, the separate joint site speciﬁc ROA
scores (0e2) were added together as co-variables in the
analysis. Especially subjects with hip, hand and high
WOMAC scores independently load onto the ﬁrst compo-
nent, subjects with especially knee ROA and high WOMAC
scores load on the second component whereas, subjects
with facet and hand ROA and DD ROA load onto the third
component. The estimates in Table IV should be interpreted
relative to the ranges of the scores that are equal for knee,
facet, hip and hand and DD (0e2), however, larger for the
total ROA score (0e10) and clinical symptoms (0e100).
Discussion
In the present study, it was investigated whether OA
patients may be discriminated on the basis of biochemical
marker patterns and whether the pattern may reﬂect differ-
ent aspects of the pathophysiology of OA. The GARP study
provided a unique study population since radiographs and
symptoms were registered for knee, hip, hand, facet joints
as well as intervertebral discs. The principal component
Table III
PCA of biochemical marker levels, BMI and age of the sample of
the GARP study (N¼ 289)
Process Marker Component
1 2 3
Cartilage degradation CTX-II 0.85
Cartilage degradation TIINE 0.80
Synovial tissue turnover GlceGal-PYD 0.72
Bone resorption CTX-I 0.64
Bone formation Total OC 0.48
BMI 0.76
Inﬂammation HsCRP 0.69
Collagen synthesis PIIANP 0.59
Cartilage turnover COMP 0.70
Age 0.60
Variance explained (%) 27 18 12
PCA using a Varimax rotation with Kaiser Normalization. Compo-
nents with Eigen values >1 are extracted, coefﬁcients with values
>0.4 are displayed.analyses of eight different markers showed that the data
may be reduced to three independent underlying dimen-
sions (components) that may reﬂect the most predominant
pathophysiological processes of OA. The coefﬁcients in
Table III show how well each individual marker is able to
represent a particular component and may enable a more
suitable choice in measuring markers for different pro-
cesses. We found that the CTX-II levels clustered with
TIINE, CTX-I, total OC, and GlueGal-PYD, especially in
subjects with hip, facet, hand and knee ROA (Table IV),
indicating that ROA in these joint locations coincide with
alterations of the cartilage, bone and synovial tissue metab-
olism. This result was almost identical with the previously
observed association of the CTX-II within the GARP study3
and the ﬁndings recently reported by Garnero et al. in
patients with hip OA4.
We also found that HsCRP, a well established non-spe-
ciﬁc molecular marker of systemic inﬂammation, consis-
tently co-occurs together with BMI. We show here that
this relation may be speciﬁcally for subjects with knee
ROA and high WOMAC scores. Given the fact that the level
of HsCRP, in general, is inﬂuenced by many factors we
cannot exclude the presence of additional confounders.
The WOMAC score consists of three subscales: pain (ﬁve
items), stiffness (two items), and function (17 items) that
may be used as separate scales. When the subscales are
entered as co-variables in mixed model regression analysis
especially the function scale appears to associate to the
second component. Together these results may indicate
a pathophysiological process for knee ROA involving BMI
and an inﬂammatory process. In the current cross sectional
analysis we are, however, not able to assess a causal rela-
tionship and needs to be investigated in a follow-up design.
The third component was represented by COMP and
PIIANP levels, clustered with age and occurs especially
among subjects with facet, hand ROA and spinal DD. Al-
though COMP has initially been proposed as a cartilage-
speciﬁc molecule, it has subsequently been shown to be
synthesized also by ligament, tendon, and synovial ﬁbro-
blasts, and osteoblasts and has recently been suggested
to reﬂect cartilage breakdown and/or inﬂammation of the sy-
novial membrane4. In our study we did not ﬁnd evidence for
an inﬂammatory component of COMP. However, we ob-
served that COMP together with PIIANP may be under ge-
netic inﬂuence also reﬂected by a heritable inﬂuence of the
third component (results not shown). In the heritability
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Linear relationship of extracted principal components (1e3) and OA characteristics (ROA score, clinical symptoms, sex) of the subjects
of the GARP study sample (N¼ 289)
OA characteristics Components*
1 2 3
Estimate P Estimate P Estimate P
Total ROA (0e10) 0.16 0.0001 0.06 0.054 0.16 0.0001
Sex 0.32 0.014 0.12 0.337 0.18 0.142
WOMAC (0e100)y 0.01 0.002 0.01 0.0001 0.00 0.214
Knee (0e2) 0.18 0.014 0.19 0.008 0.09 0.194
Facet (0e2) 0.20 0.016 0.05 0.554 0.26 0.001
Hip (0e2) 0.38 0.0001 0.14 0.113 0.03 0.697
Hand (0e2) 0.17 0.015 0.01 0.919 0.14 0.033
DD (0e2) 0.03 0.713 0.11 0.179 0.24 0.002
Sex 0.31 0.020 0.15 0.264 0.19 0.124
WOMAC (0e100)y 0.01 0.002 0.01 0.0001 0.03 0.239
*Component 1 represents subjects with high UCTX-I and -II, total OC, GlceGal-PYD; Component 2 represents subjects with high levels of
HsCRP and high BMI; component 3 represents subjects with high PIIANP, COMP and age.
yTotal WOMAC score. Data were analyzed using mixed model regression analyses with the components as dependent variable and as co-
variables the presence of clinical symptoms and sex in addition to either the total ROA score or the joint site speciﬁc ROA score of the knee,
facet, hip, hand and DD.analyses for COMP adjustments were necessary for the
presence of ROA, and age. Given these results we propose
that among subjects of the GARP study, COMP and PIIANP
levels may be inﬂuenced independently by ROA, age and
heritable factors. Due to the high correlation between
ROA and age in our study group we are not able to distin-
guish to what extent there is also a genetic predisposition
to age related COMP levels irrespective of the presence
of OA and vice versa. These age related aspects of
COMP and PIIANP need to be investigated further among
subjects without ROA. Genetic studies may reveal genes
inﬂuencing the variation in these levels.
To compensate, at least in part, for the amount of carti-
lage of the small joints of the hands as compared to for ex-
ample the hip joints we have used the proportioned ROA
score for each joint location. Furthermore the estimates
provided in Table IV were assessed independently of the
effect of ROA at other joint locations. Given the cartilage
volumes of the large joints (knees and hips) as compared
to the small joints (hand, facets and discus degeneration
of the spine), however, estimates for the small joints may
be underestimated and for the large joints (especially the
knee with different compartments) overestimated.
In a study of Sharif et al.14 it was shown that COMP levels
remain elevated in the period (up until 1 year) following re-
placement of the knee. We have, therefore, considered sub-
jects with recent joint replacements as having ROA at that
respective joint. When data were analyzed with all arthro-
plastic joints as ROA absent or missing, the model appears
to ﬁt to a lesser extent, especially for component 1 and hip
ROA. These results may indicate that also biochemical
markers levels of cartilage and bone turnover remain ele-
vated after joint replacement surgery. Furthermore, it has
previously been shown that joint space narrowing may pro-
vide more valid correlation of biochemical marker re-
sponses. When joint space narrowing and osteophyte
scores for either knee or hip were analyzed separately,
we did not observe such a relationship.
It should be noted that, because the dynamics of each
biochemical marker differ between separate body compart-
ments, i.e., serum and urine, the results of our principal
component analyses should be interpreted with cautionand should be conﬁrmed by other studies using measure-
ments of all markers in the same biological ﬂuid.
Since our study has OA data available from most preva-
lent ROA joint locations, i.e., hips, knees, facet, hands and
DD of the spine, our results are not likely to be confounded
by ROA at joint locations for which radiographic data were
lacking. The absence of radiographic data for example of
shoulders and diarthroidial joints may, however, have
caused some bias. This paper concerned cross sectional
data, we could, therefore, not assess the potential predic-
tive value of the biochemical markers to predict disease pro-
gression. Furthermore, the women in our study consist
mainly of postmenopausal women, some of our ﬁndings
may therefore not apply to younger women or postmeno-
pausal women receiving HRT.
Based on the results of the present study, we propose
that classiﬁcation of OA patients by biochemical marker
levels may indicate three speciﬁc molecular mechanisms
primarily involving (1) structural markers of bone turnover,
cartilage degradation and synovial involvement; (2) inﬂam-
mation; and (3) age related changes. Our data also suggest
that some of these processes may have a genetic compo-
nent and especially contribute to OA development at spe-
ciﬁc joints. Further research is necessary to establish the
association of these markers with progression of OA.
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